Previous 10 | Next 10 |
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in form...
2023-10-19 19:15:23 ET Summary Positive interim analysis from its phase 2 CALLIPER study achieved, showing a statistically significant reduction in neurofilament light chain (NfL) in progressive multiple sclerosis patients when given vidofludimus calcium. Vidofludimus calcium perf...
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 PR Newswire NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology compa...
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 PR Newswire NEW YORK , Oct. 15, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a c...
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting PR Newswire – Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms o...
--News Direct-- Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for progressive multiple sclerosis...
2023-10-10 10:09:18 ET DENVER, Colo., Oct. 10, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SMX (Security Matters) (NASDAQ: SMX), Immunic (NASDAQ: IMUX), Intrusion (NASDAQ: INTZ), SuperCom (NASDAQ: SPC...
2023-10-10 09:36:15 ET DENVER, Colo., Oct 9, 2023 ( www.247marketnews.com )- Immunic, Inc. (NASDAQ: IMUX) reported, after yesterday’s market close, positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838...
2023-10-09 17:05:57 ET More on Immunic Immunic, Inc. (IMUX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Immunic Financial information for Immunic For further details see: Immunic jumps after the bell on positive interim data fr...
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Mul...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...